Earnings call transcript: Cadre Holdings Q1 2026 results miss forecasts, stock dips

Cadre Holdings reported Q1 2026 EPS of $0.05 versus $0.10 expected, a 50% miss, while revenue came in at $155.4 million versus $156.66 million consensus. Shares fell 4.92% in after-hours trading, though revenue still grew 19% year over year and management reaffirmed 2026 guidance for $736 million-$758 million in sales and $136 million-$141 million of adjusted EBITDA. Record backlog of $355 million and ongoing integration of TYR Tactical and Alien Gear support the longer-term outlook, but near-term softness in distribution and a mixed earnings print temper sentiment.

Analysis

The cleanest read-through is not that Cadre had a bad quarter, but that the market is repricing the quality of its earnings mix. When a high-multiple industrial misses by a wide margin while still posting decent top-line growth, the problem is usually not demand collapse; it is timing, mix, and incremental margin conversion. That matters because backlog is now doing more of the narrative work than realized earnings, so the stock is likely to stay hostage to each quarter’s shipment cadence rather than to the longer-dated demand story.

The second-order winner is likely the broader defense/public-safety supply chain tied to replacement cycles and budgeted procurement, not Cadre itself. If management is right that backlog is largely shippable over the next 2-3 quarters, this becomes a deferred revenue visibility story, which is constructive for suppliers of subcomponents and contract manufacturers with less execution risk. The softer distribution channel is the real canary: it suggests discretionary attach rates are weakening before mission-critical spend does, which means the next leg of margin pressure would likely show up first in lower-ticket products and only later in core safety lines.

The key risk is that investors have given Cadre credit for “steady compounder” economics, while the acquisition-heavy strategy is temporarily obscuring organic quality. If TYR and Alien Gear take longer to integrate, the market will punish the stock for any further EPS misses because it has no tolerance for integration slippage at ~34x earnings. Conversely, if management can prove that Q2 is the trough and back-half margins snap back with volume, the current selloff can reverse quickly over the next 1-2 earnings cycles; the setup is more of a credibility trade than a secular one.

Contrarian view: the move may be somewhat overdone if backlog conversion is truly concentrated in H2 and if the miss was mostly timing, not demand destruction. But the market is correctly discounting that the easy acquisition lift has already been capitalized, while the remaining upside depends on flawless execution in a tougher macro and budget environment. In that sense, the stock is less a cheap defense compounder and more a levered execution story with a still-high bar.

Key Decisions for Investors

• Avoid adding to CDRE ahead of the next print; wait 1-2 quarters for proof that backlog converts into margin expansion before re-rating the multiple.
• If already long CDRE, sell covered calls against the position into any post-earnings bounce; the implied path is choppy and the valuation leaves little room for another miss.
• Consider a tactical short in CDRE vs. long a higher-quality defense prime or industrial supplier with clearer organic growth and lower integration risk over the next 3-6 months.
• For event-driven traders, buy CDRE only on a confirmed margin inflection in Q2/Q3 with volume confirmation; the trade needs evidence, not backlog rhetoric.
• If looking for a contrarian rebound, use call spreads rather than outright longs in CDRE for the next 60-90 days to limit downside if integration or distribution softness persists.